tradingkey.logo

Biomarin Pharmaceutical Expects Q3 Will Include Acquired Ipr&D Charges Of About $221 Million

ReutersOct 7, 2025 9:55 PM

- Biomarin Pharmaceutical Inc BMRN.O:

  • BIOMARIN PHARMACEUTICAL INC: EXPECTS Q3 WILL INCLUDE ACQUIRED IPR&D CHARGES OF APPROXIMATELY $221 MILLION ON A PRE-TAX BASIS DUE TO INOZYME PHARMA DEAL

  • BIOMARIN PHARMACEUTICAL INC - FOR Q3, CO EXPECTS CHARGE OF ABOUT $1.10 TO BOTH GAAP AND NON-GAAP EPS DUE TO INOZYME PHARMA DEAL

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI